David Paling

Phenytoin for neuroprotection in patients with acute optic neuritis: a randomised, placebo-controlled, phase 2 trial

Rhian Raftopoulos, Simon J. Hickman, Ahmed Toosy et al. · The Lancet Neurology · 2016 · 195 citations · Full text

Medicine, Neurology, Neuroscience +11

Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial

Jeremy Chataway, Floriana De Angelis, Peter Connick et al. · The Lancet Neurology · 2020 · 130 citations · Full text

Medicine, Neurology, Pharmacotherapy +17

Sodium accumulation is associated with disability and a progressive course in multiple sclerosis

David Paling, Bhavana Solanky, Frank Riemer et al. · Brain · 2013 · 122 citations · Full text

Medicine, Neurology, Neuroscience +17

Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammation

Emma Tallantyre, Dan Whittam, Stephen Jolles et al. · Journal of Neurology · 2018 · 85 citations · Full text

Life Sciences, Immunology, Neurology +17

Cerebral Arterial Bolus Arrival Time is Prolonged in Multiple Sclerosis and Associated with Disability

David Paling, Esben Thade Petersen, Daniel J. Tozer et al. · Journal of Cerebral Blood Flow & Metabolism · 2013 · 73 citations · Full text

Medicine, Neurology, Neuroscience +16